ThromboGenics’ lead product JETREA® (ocriplasmin) is the first approved pharmacological treatment for symptomatic vitreomacular adhesion (VMA)/vitreomacular traction (VMT).
The US Food and Drugs Administration (FDA) approved JETREA® for the treatment of symptomatic VMA in October 2012. ThromboGenics launched the drug in the US by its own commercial organization in mid-January 2013.
In March 2013, the European Commission approved JETREA® for VMT, including when associated with macular hole of diameter less than or equal to 400 microns. Alcon, ThromboGenics’ partner for the commercialization of JETREA® outside the US, has now launched the drug in the UK, Germany, Denmark, Sweden, Norway and Finland.
Next to an overview of ThromboGenics, speakers will elaborate on their strategic partnership with Alcon (Novartis) for the commercialization of JETREA® outside the United States as well as on the regulatory path, its challenges and learnings.
ThromboGenics is headquartered in Leuven, Belgium, and has-offices in Iselin, NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR.
Date: Wednesday October 9th, 2013 (18h00 – 21h30)
Location: ThromboGenics, Bio-Incubator II, Gaston Geenslaan 1, 3001 Leuven
|18h30:||Welcome by Leuven.Inc|
|18h40:||Introduction and overview of ThromboGenics
Désiré Collen, Prof.em. KU Leuven, oprichter en huidig voorzitter, ThromboGenics
|19h00:||JETREA® indication and mode of action
Petra Kozma-Wiebe, Clinical Trials Physician, ThromboGenics
|19h30:||Regulatory path for JETREA®: challenges and learnings
Lene Rose Arfelt, Global Head Regulatory Affairs, ThromboGenics
|20h00:||Q&A followed by a reception|
|21h30:||Closing of the Café|
Registration before Wednesday 2 October, preferably via the online registration form (use the 'Register' button) or by email to firstname.lastname@example.org (including all contact and invoice details).
Please note: Leuven.Inc Ondernemerscafés are a members-only activity.
For organizational reasons, the number of participants will be limited.
Company members (max. 2 persons/company) will have first priority to register till September 6.
After this date, individual members can register according to the 'first subscribe, first serve' principle.
After registration you will receive a confirmation and route description.
May we kindly ask you to inform us in case you are not able to attend.